Water Cooler Chat: Expedite your clinical study with a Pre-IND, speed-to-study Strategy

Is your drug product manufactured outside of the United States? Do you have challenging dosing milestones?

Implementing a Pre-IND packaging strategy will expedite your upstream timeline to ensure you meet your first patient-in milestones while you await your FDA approval and IND number.

On September 2nd, Olivia Burgess (General Manager of our Canadian Operations), Sharlett Burgess (Quality Director of Canada) and Jackie Newell (Business Development Manager) will be discussing the in’s and out’s of the Pre-IND speed-to-study™ offering, including the quality and regulatory considerations, and how introducing this process into your overall clinical supply strategy will accelerate your trial and attain your FPI milestones.”

To book your space on 02 September, 2021, please click here: